Inhibition of Plk1 significantly increases NF-κB phosphorylation at Ser468, reactivating anti-tumor immunity and restoring sensitivity to immune checkpoint blockade, particularly anti–PD-L1 therapy (11). This evidence concerns the gene NFKB1 and neoplasm.